Fate THERAPEUTICS

Better Cells For Better Therapies™

Off-the-shelf Cell-based Cancer Immunotherapy

Developing First-of-kind Cell Products using Clonal Master iPSC Lines

2019 ASH Dinner Discussion

December 6, 2019



Fate THERAPEUTICS

Better Cells For Better Therapies™

Join Us for Dinner During the ASH Annual Meeting

Friday, December 6, 2019
7:00 - 9:00pm

Hyatt Regency Orlando
9801 International Drive
Orlando, FL 32819

RSVP by November 29
Michael Horowicz
michael.horowicz@sternir.com
212.362.1200

Initial clinical data of FT500, first-ever iPSC-derived cell therapy to undergo U.S. clinical investigation, to be highlighted

Special Guest Speakers

Jeffrey S. Miller, MD
Deputy Director, Masonic Cancer Center
Director, Cancer Experimental Therapeutics Initiative (CETI), University of Minnesota

Michel Sadelain, MD, PhD
Director, Center for Cell Engineering, Memorial Sloan Kettering Cancer Center

Eric Smith, MD, PhD
Director of Clinical Translation, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center

ASH Oral Presentations

FT538: Preclinical Development of an Off-the-Shelf Adoptive NK Cell Immunotherapy with Targeted Disruption of CD38 to Prevent Anti-CD38 Antibody-Mediated Fratricide and Enhance ADCC in Multiple Myeloma When Combined with Daratumumab
Saturday, December 7, 2019, 9:30 AM, W415A

FT596: Translation of First-of-Kind Multi-Antigen Targeted Off-the-Shelf CAR-NK Cell with Engineered Persistence for the Treatment of B Cell Malignancies
Saturday, December 7, 2019, 4:00 PM, W415A

Forward-Looking Statements

This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company's research and development activities and its progress, plans and timelines for its manufacture, preclinical development and clinical investigation of its product candidates, the timing for the Company's receipt of data from its clinical trials and preclinical studies, the Company's clinical development and regulatory strategy, and the therapeutic and market potential of the Company's product candidates. These and any other forward-looking statements in this presentation are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that results observed in prior studies of its product candidates will not be observed in ongoing or future studies involving these product candidates, the risk of a delay in the initiation of, or in the enrollment or evaluation of subjects in, any clinical studies, and the risk that the Company may cease or delay manufacture, or preclinical or clinical development, of any of its product candidates for a variety of reasons (including regulatory requirements, difficulties in manufacturing or supplying the Company's product candidates, and any adverse events or other negative results that may be observed during preclinical or clinical development). These statements are also subject to other risks and uncertainties as further detailed in the Company's most recently filed periodic report, and subsequent periodic reports filed by the Company, under the Securities Exchange Act of 1934, as amended, any of which could cause actual results to differ materially from those contained in or implied by the forward-looking statements in this presentation. The Company is providing the information in this presentation as of the date hereof and does not undertake any obligation to update any forward-looking statements contained in this presentation unless required by applicable law.

Fate THERAPEUTICS

Introduction

2019 – A Break-through Year for the FATE iPSC Product Platform

Feb 2019 – First-ever Patient Treated with an iPSC-derived Cell Therapy in U.S.

UC San Diego
MOORES CANCER CENTER

FT500

From left: Sandip Patel, MD; Dan Kaufman, MD, PhD; Derek Ruff

Fate THERAPEUTICS

2019 – A Break-through Year for the FATE iPSC Product Platform

Oct 2019 – First-ever Patients Treated with Cell Therapy derived from a Clonal Master Engineered iPSC Line

University of Minnesota opens first-ever U.S. clinical trial of engineered iPSC-derived cell therapy for blood cancers

UNIVERSITY OF MINNESOTA
Driven to Discover℠

MINNEAPOLIS, MN- October 21, 2019 - A new cancer clinical trial has opened at the M Health Fairview University of Minnesota Medical Center that leverages the groundbreaking research on stem cells and natural killer (NK) cells done at the Masonic Cancer Center and applies it to attack acute myeloid leukemia (AML) and B-cell lymphoma. The first-of-its-kind NK cell cancer immunotherapy, called FT516, is manufactured from a human induced pluripotent stem cell (iPSC) that has been genetically engineered to enhance its anti-tumor activity.

Claudio Brunstein, MD, PhD

The first-in-human clinical trial of FT516, sponsored by Fate Therapeutics, will be run locally by Claudio Brunstein, MD, PhD, who is a professor of Medicine at the U of M Medical School, a member of the Masonic Cancer Center, and the medical director of the Adult Blood and Marrow Transplant and Cellular Therapy Program at M Health Fairview.

"We potentially have an unlimited source of very similar, reproducible cancer fighters," said Brunstein. "This is opening a whole new door in cellular therapy. With increased modifications to these NK cells, we can elevate their ability to attack tumors. As we add more functionality to NK cells, we have the potential to bring together multiple anti-tumor mechanisms and more effectively target and kill cancer."

Fate THERAPEUTICS

2019 – A Break-through Year for the FATE iPSC Product Platform

Sept 2019 – Secured FDA Clearance of IND Application for First-ever Cell Therapy Engineered with Three Anti-Tumor Modalities

Fate Therapeutics Announces the Opening of its cGMP Manufacturing Facility Dedicated to iPSC-derived Cell Therapies

State-of-the-Art Facility Designed to use Clonal Master iPSC Lines as Renewable Cell Source for Manufacture of Off-the-Shelf Product Pipeline

San Diego, CA – September 30, 2019 – Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company has opened its current Good Manufacturing Process (cGMP) compliant manufacturing facility for the clinical production of its off-the-shelf natural killer (NK) cell and chimeric antigen receptor (CAR) T-cell product candidates. The

- *Completed GMP production of FT596 at FATE facility in November*
- *Single "small-batch" manufacturing campaign yielded ~320 cryopreserved, infusion-ready doses*
- *Estimated actual cost per dose: <$2,500*

Fate THERAPEUTICS

2019 – A Break-through Year for the FATE iPSC Product Platform

Aug 2019 – Issuance of Foundational U.S. Patent Covering iPSC-derived CAR T Cells

United States Patent
Themeli et al.

Patent No.: US 10,370,452 B2
Date of Patent: Aug. 6, 2019

EFFECTIVE GENERATION OF TUMOR-TARGETED T CELLS DERIVED FROM PLURIPOTENT STEM CELLS

Applicant: **MEMORIAL SLOAN-KETTERING CANCER CENTER**, New York, NY (US)

Inventors: **Maria Themeli**, New York, NY (US); **Michel Sadelain**, New York, NY (US); **Christopher C. Kloss**, New York, NY (US)

Assignee: **MEMORIAL SLOAN-KETTERING CANCER CENTER**, New York, NY (US)

Claim 1. A population of T cells that are produced by in vitro differentiation of a pluripotent stem cell, wherein (i) the pluripotent stem cell expresses a chimeric antigen receptor (CAR), and (ii) the population of T cells comprises a T cell exhibiting a CD45RA+ CD27- CD28- CCR7- CD62L- phenotype.

iPSC-derived CAR T-cell Phenotype



- ***Priority Date = April 3, 2013***
- ***Publication Date = October 9, 2014***

Fate THERAPEUTICS

2019 – A Break-through Year for the FATE iPSC Product Platform

Dec 2019 – No Morphologic Evidence of Leukemia, with Complete Neutrophil Recovery, Observed in First Patient Treated with FT516 Monotherapy for AML

41 year old male diagnosed with AML in January 2019

- Refractory to initial induction therapy and multiple additional lines of therapy

Enrolled in FT516 Study (Oct 2019)

- Early assessment following first three doses of FT516 with IL-2 cytokine support showed:
  - No morphologic evidence of leukemia, with evidence of hematopoietic recovery, in bone marrow
  - No circulating leukemic blasts in peripheral blood
  - Recovery of neutrophils (>1,000 per µL)
  - No observed CRS, neurotoxicity or GvHD
  - FT516 chimerism detected *in the bone marrow* at Day 18 by digital PCR

Fate THERAPEUTICS

Off-the-Shelf T-cell Immunotherapy

Fate THERAPEUTICS
Better Cells For Better Therapies™

FT819 Universal, Off-the-Shelf CAR19 T-Cell Product

Novel CAR19 Targeted to the TRAC Locus for Improved Safety and Efficacy

First-in-Class Off-the-Shelf Adoptive CAR19 T cell Product Uniformly Consisting of Novel Engineering Elements



1XX CAR19: Novel chimeric antigen receptor consisting of CD28 costimulatory domain and modified CD3z signaling domain for optimal effector cell persistence and anti-tumor potency

---

TRAC targeted CAR: Chimeric antigen receptor integrated into the T Cell Receptor Alpha Constant region to be regulated by endogenous control of TCR expression for optimal CAR performance

---

TCR null: Bi-allelic disruption of TRAC at the clonal level for complete removal of TCR expression and the elimination for the possibility of GvHD in allogeneic setting

1H20 IND Submission Planned

Fate THERAPEUTICS
Better Cells For Better Therapies™

Memorial Sloan Kettering Cancer Center™

Using Single-Cell iPSC System to Conduct Complex Engineering

TRAC targeted, TCR less, 1XX CAR19 T cell Product Profile Comparison

LETTER

doi:10.1038/nature21405

Targeting a CAR to the *TRAC* locus with CRISPR/Cas9 enhances tumour rejection

Justin Eyquem[1]*, Jorge Mansilla-Soto[1]*, Theodoros Giavridis[1], Sjoukje J. C. van der Stegen[1], Mohamad Hamieh[1], Kristen M. Cunanan[2], Ashlesha Odak[1], Mithat Gönen[2] & Michel Sadelain[1]

T cell procurement selection & activation

Pool engineering

Desired cell enrichment

Desired cell Expansion

Pool Engineered Primary T Cells



vs.

Thaw of engineered master iPSC line

iCD34 differentiation

iT differentiation

iT expansion

Single-cell Engineered iPSC-derived T cells



Fate THERAPEUTICS
Better Cells For Better Therapies™

FT819 Path to IND – iPSC Clone Generation

Multi-parameter iPSC engineering, clone screening and MCB selection



1. Regulated CAR expression for enhanced function
2. Elimination of TCR expression to avoid GvHD
3. Introduce next gen CAR1XX for optimized CAR signaling

Number of clones passing in-process testing

Clones with Desired Attributes

- iPSCs Expanded — 774
- Biallelic, specific TRAC-targeted clones
- Clones Maintaining Pluripotency
- Clones free of reprogramming vectors
- Clones demonstrating genomic stability
- Clones without off-target edits — 19
- Clones with ideal propensity to become T cells
- Clones with desired CAR anti-tumor specificity — 1
- Selected MCB

Molecular testing

Functional testing

Fate THERAPEUTICS
Better Cells For Better Therapies™

Memorial Sloan Kettering Cancer Center™

Memorial Sloan Kettering Cancer Center

New Directions in CAR T Cell Engineering
From current CD19 CAR therapy *to FT819*

Michel Sadelain, MD, PhD
Director, Center for Cell Engineering
Memorial Sloan Kettering Cancer Center
New York, NY

The rise of CAR T cell therapy (1)

Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor

John Maher, Renier J. Brentjens, Gertrude Gunset, Isabelle Rivière, and Michel Sadelain*

Nature Biotechnology, 2002

Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15

Renier J. Brentjens[1], Jean-Baptiste Latouche[1], Elmer Santos[1,2], Francesc Marti[5], Michael C. Gong[1], Clay Lyddane[1,3], Philip D. King[5], Steven Larson[2], Mark Weiss[1], Isabelle Rivière[1,3,4] & Michel Sadelain[1,3,4]

Nature Medicine, 2003

Memorial Sloan Kettering Cancer Center

The rise of CAR T cell therapy (2)

2019
430 studies registered
at clinicaltrials.gov



Memorial Sloan Kettering Cancer Center

Rapid and complete eradication of refractory leukemia by 19-28z CAR T cells



Brentjens, Davila, Rivière *et al*,
Science Transl Med, March 2013

Breakthrough of the year
Science, December 2013

Table 1. Reponses to CAR T-Cell Therapy.*

Disease	Response Rate	Comments	Reference
	percent		
Leukemia			
B-cell acute lymphoblastic leukemia (in adults)	83–93	High initial remission rates; unresolved issue is whether CAR T-cell therapy is definitive therapy or should be followed by allogeneic hematopoietic stem-cell therapy	Park et al.,[35] Davila et al.,[36] Turtle et al.[37]
B-cell acute lymphoblastic leukemia (in children)	68–90	Approximately 25% of patients reported to have a relapse with CD19-negative or CD19-low leukemia; CD22 CAR T cells may improve survival among some patients with CD19 relapses	Maude et al.,[34] Maude et al.,[38] Fry et al.,[39] Lee et al.[40]
Chronic lymphocytic leukemia	57–71	Relapse is rare in patients who have a complete response; ibrutinib appears to increase response rates	Porter et al.,[41] Turtle et al.[42]
Lymphoma			
Diffuse large B-cell lymphoma	64–86	Approximately 40–50% of patients reported to have a durable complete response	Turtle et al.,[43] Kochenderfer et al.,[44] Schuster et al.,[45] Neelapu et al.[46]
Follicular lymphoma	71	At a median follow-up of 28.6 mo, the response was maintained in 89% of patients who had a response	Schuster et al.[45]
Transformed follicular lymphoma	70–83	A total of 3 of 3 patients with transformed follicular lymphoma had a complete response	Turtle et al.,[43] Schuster et al.,[45] Neelapu et al.[46]
Refractory multiple myeloma	25–100	B-cell maturation antigen CAR T cells; stringent complete response in approximately 25% of patients	Ali et al.,[47] Fan et al.,[48] Berdeja et al.[49]
Solid tumors			
Glioblastoma	ND	{q4}In case report from phase 2 study, complete response on magnetic resonance imaging after intravenous and cerebrospinal fluid administration of CAR T cells; complete response lasted 7.5 mo	Brown et al.[50]
Pancreatic ductal adenocarcinoma	17	In one patient with liver metastasis, CAR T-cell treatment produced a complete metabolic response in the liver but was ineffective against the primary pancreatic tumor	Beatty et al.[51]

* ND denotes not determined.

June and Sadelain,
N Engl J Med, 2018

Memorial Sloan Kettering Cancer Center

Rapid and complete eradication of refractory leukemia by 19-28z CAR T cells



Brentjens, Davila, Rivière *et al*,
Science Transl Med, March 2013

Breakthrough of the year
Science, December 2013

Table 1. Reponses to CAR T-Cell Therapy.*

Disease	Response Rate	Comments	Reference
	percent		
Leukemia			
B-cell acute lymphoblastic leukemia (in adults)	83–93	High initial remission rates; unresolved issue is whether CAR T-cell therapy is definitive therapy or should be followed by allogeneic hematopoietic stem-cell therapy	Park et al.,[35] Davila et al.,[36] Turtle et al.[37]
		Approximately 25% of patients reported to have a relapse with CD19-negative or CD19-low leukemia; CD22 CAR T cells may improve survival among some patients with CD19 relapses	Maude et al.,[14] Maude et al.,[38] Fry et al.,[39] Lee et al.[40]
		Relapse is rare in patients who have a complete response; ibrutinib appears to increase response rates	Porter et al.,[41] Turtle et al.[42]
		Approximately 40–50% of patients reported to have a durable complete response	Turtle et al.,[43] Kochenderfer et al.,[44] Schuster et al.,[45] Neelapu et al.[46]
		At a median follow-up of 28.6 mo, the response was maintained in 89% of patients who had a response	Schuster et al.[45]
		A total of 3 of 3 patients with transformed follicular lymphoma had a complete response	Turtle et al.,[43] Schuster et al.,[45] Neelapu et al.[46]
		B-cell maturation antigen CAR T cells; stringent complete response in approximately 25% of patients	Ali et al.,[47] Fan et al.,[48] Berdeja et al.[49]
		{q4}In case report from phase 2 study, complete response on magnetic resonance imaging after intravenous and cerebrospinal fluid administration of CAR T cells; complete response lasted 7.5 mo	Brown et al.[50]
		In one patient with liver metastasis, CAR T-cell treatment produced a complete metabolic response in the liver but was ineffective against the primary pancreatic tumor	Beatty et al.[51]

* ND denotes not determined.

June and Sadelain,
N Engl J Med, 2018

Memorial Sloan Kettering Cancer Center



FDA approved in 2017

Axicabtagene Ciloleucel	Tisagenlecleucel
(Yescarta)	(Kymriah)

Prototypic CD19 CARs

Clinical Success in B cell leukemia and lymphoma

ALL

Lymphoma

Overall Survival

CD28 CAR





(Park JH et al, NEJM 2018)



(Neelapu SS et al, NEJM 2017)

Event-free and Overall Survival

4-1BB CAR





(Maude SL et al, NEJM 2018)



(Schuster SJ et al, NEJM 2018)

Memorial Sloan Kettering Cancer Center

Increasing CAR therapy efficacy and availability

1. Regulated CAR expression
2. Titrated CAR signaling
3. “Off-the-shelf” TiPSC – derived CAR T cell production

Viral vector integration – variegated expression

MLV-based vector



Zhao et al., Cancer Cell , 2015



HIV-based vector



Milone et al., Mol. Therapy , 2009



Memorial Sloan Kettering Cancer Center

CRISPR/Cas9-targeted integration into the *TRAC* locus







Justin Eyquem, PhD

J. Mansilla-Soto, PhD



Eyquem, Mansilla-Soto et al, *Nature*, 2017

Memorial Sloan Kettering Cancer Center

CRISPR/Cas9-targeted integration into the *TRAC* locus







Eyquem, Mansilla-Soto et al, *Nature*, 2017

Memorial Sloan Kettering Cancer Center

TRAC-CAR T cells are less exhausted in vivo
CAR surface expression is down-regulated upon exposure to antigen





Eyquem, Mansilla-Soto et al, *Nature*, 2017

Memorial Sloan Kettering Cancer Center

Summary *TRAC*-CAR



- *TRAC*-1928z T cells show enhanced in *vivo* anti-tumor activity relative to RV/LV CAR T cells
- The TCR alpha promoter provides highly homogeneous and optimal control of 1928z CAR expression
- *TRAC*-1928z sustains functional persistence by averting rapid T cell differentiation and exhaustion
- Established link between CAR expression level and therapeutic activity.
- Simultaneous CAR knock-in and TCR knock-out enables allogeneic application

Memorial Sloan Kettering Cancer Center

ITAM-based calibration of activation strength in CD28/CD3ζ CARs







Feucht, Sun, *Nat Med* 2019

Memorial Sloan Kettering Cancer Center

1928ζ ITAMs differentially regulate CAR T cell potency





Memorial Sloan Kettering Cancer Center

TRAC-1XX CAR T cells promote memory and protect against tumor re-challenge



Feucht, Sun, *Nat Med* 2019

CAR ITAM-calibration directs T cell fate



Judith Feucht, MD



Sun Jie, PhD



Feucht, Sun, *Nat Med* 2019

Memorial Sloan Kettering Cancer Center

Summary 1XX



- CD3ζ ITAM domains within 1928ζ CARs direct qualitatively different CAR T cell functions
- ITAM number & position within 1928ζ CARs impact CAR function
- CD3ζ ITAM mutations direct T cells to different fates by balancing effector and memory programs
- 1XX leads to fast & efficient long-term tumor eradication by inducing strong effector function without shutting off memory programs
- Further reducing activation potential (XX3) results in high CAR persistence, but insufficient effector function

Memorial Sloan Kettering Cancer Center

Where do T cells and their natural receptor come from

Thymic origin, VDJ recombination and clonal selection





Jacques Miller



Immunobiology: The Immune System in Health and Disease. 5th edition. Janeway CA Jr, Travers P, Walport M, et al. New York: Garland Science; 2001.

The clonal selection theory

•Each lymphocyte bears a single receptor with a unique specificity. • Interaction between a foreign molecule and a lymphocyte receptor capable of binding that molecule with a high affinity leads to lymphocyte activation and clonal expansion. • Lymphocytes bearing receptors specific for ubiquitous self molecules are deleted at an early stage in lymphoid cell development and are therefore absent from the repertoire of mature lymphocytes.



F. Macfarlane Burnet

Memorial Sloan Kettering Cancer Center

“Off-the-shelf” CAR T cells produced from pluripotent stem cells



Adapted from: Themeli, Riviere & Sadelain, *Cell Stem Cells*, 2015

TiPSC differentiation – reconciling Notch, pre-TCR, TCR and CAR

1. Early TCRαβ expression
2. Notch stimulation
3. CAR expression

Sjoukje van der Stegen



Memorial Sloan Kettering Cancer Center

$CD4^+CD8\alpha\beta^+$ DP T cell development – Central roles of TCR and Notch signaling





Maria Themeli
Sjoukje van der Stegen

Memorial Sloan Kettering Cancer Center

CAR expression influences DP T cell development

early





late

















Memorial Sloan Kettering Cancer Center

Solutions: *TRAC*-1928z TiPSC-derived T cells







early



late



Memorial Sloan Kettering Cancer Center

Solutions: ITAM-control enhances $\alpha\beta$ lineage fate





Memorial Sloan Kettering Cancer Center

Summary T-iPSC



- Early TCRαβ expression skews T cell differentiation
- hDLL4 can induce CD4/CD8 DP T cells
- CD8 SP T cells arise from DP population

- CAR expression interferes with DP T cell development
- Delayed CAR expression can facilitate DP > SP conversion

- *TRAC*-encoded CAR expression with controlled ITAM strength enhances αβ T cell development

FT819 Phenotype, Potency, Specificity and Proliferation Capacity

Derived from a TRAC-targeted CD19 CAR, TCR-null Master iPSC line









Fate THERAPEUTICS
Better Cells For Better Therapies™

Memorial Sloan Kettering Cancer Center™

FT819 Controls Tumor Growth and Promotes Long-term Survival

Intraperitoneal Xenograft Model of Lymphoblastic Leukemia







Fate THERAPEUTICS
Better Cells For Better Therapies™

Memorial Sloan Kettering Cancer Center™

FT819 Displays Enhanced Control of Tumor Growth

Disseminated Xenograft Model of Lymphoblastic Leukemia





Fate THERAPEUTICS
Better Cells For Better Therapies™

Memorial Sloan Kettering Cancer Center™

In vitro CAR T cell development



$1x10^6$ iPSC **$5x10^7$ iCD34** **$1x10^{11}$ T-cells**

Memorial Sloan Kettering Cancer Center

From current CD19 CAR therapy *to FT819*

CAR-1XX



FDA approved in 2017

Axicabtagene Ciloleucel (Yescarta)

Tisagenlecleucel (Kymriah)

Prototypic CD19 CARs

TRAC-CAR

T-iPSC platform

Memorial Sloan Kettering Cancer Center

TiPSC for T cell immunotherapy





Antigen specificity
Targeted gene disruption
Targeted integration
Checkpoint modulation
Histocompatibility

Genotype selection

T_{SCM} T_N phenotype
CD8 or CD4 T cells
$\gamma\delta$ T cells
NKT cells
Tregs

100% purity

Memorial Sloan Kettering Cancer Center

FT819 Universal, Off-the-Shelf CAR19 T-Cell Product

Novel CAR19 Targeted to the TRAC Locus for Improved Safety and Efficacy

First-in-Class Off-the-Shelf Adoptive CAR19 T cell Product Uniformly Consisting of Novel Engineering Elements



1XX CAR19: Novel chimeric antigen receptor consisting of CD28 costimulatory domain and modified CD3z signaling domain for optimal effector cell persistence and anti-tumor potency

---

TRAC targeted CAR: Chimeric antigen receptor integrated into the T Cell Receptor Alpha Constant region to be regulated by endogenous control of TCR expression for optimal CAR performance

---

TCR null: Bi-allelic disruption of TRAC at the clonal level for complete removal of TCR expression and the elimination for the possibility of GvHD in allogeneic setting

Publication Number: 4434
Monday, December 9, 2019, 6:00 - 8:00 PM

Fate THERAPEUTICS
Better Cells For Better Therapies™

Memorial Sloan Kettering Cancer Center™

iPSC Product Innovation

iPSC Product Platform

Clonal Master iPSC Lines for Off-the-Shelf Cell Products

Single iPSC Clone

(Engineered) Single Pluripotent Stem Cell

- *Renewable*
- *Potential to differentiate into 200+ cell types*

Expansion & Banking

Unlimited Supply of Clonal Master iPSC Lines

Master Cell Bank → Working Cell Banks; Working Cell Banks; Working Cell Banks

Differentiation & Expansion

Thousands of Clonally-derived Doses of Cell Products

T Cell

Off-the-Shelf
Homogeneous | Multi-Dosing
(Engineered) Cell Products

NK Cell

"to reach more patients in need"

Fate THERAPEUTICS

Better Cells For Better Therapies™